Elicit: Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Identify clinical evidence linking TNF inhibition to outcomes in rheumatoid arthritis and psoriasis
Abstract
TNF inhibitors demonstrate substantial therapeutic efficacy for psoriatic arthritis and psoriasis, with 37% of csDMARD-inadequate responders achieving clinical improvement (ACR50) versus 8% with placebo (RR 5.63, 95% CI 3.98 to 7.96). For moderate-to-severe plaque psoriasis, PASI 75 response rates reach 80-91% with infliximab compared to 3% with placebo, with therapeutic effects appearing within 4 weeks. However, paradoxical new-onset or worsening psoriasis emerges as a recognized adverse event in patients receiving TNF inhibitors for rheumatoid arthritis, occurring at 1.04 per 1000 person-years compared to 0 per 1000 person-years with traditional DMARDs. Adalimumab shows 4.6-fold higher incidence of paradoxical psoriasis than etanercept and 3.5-fold higher than infliximab, though no statistically significant differences in therapeutic effectiveness exist among anti-TNF agents. Most patients (66%) developing paradoxical psoriasis can continue TNF inhibitor therapy with concurrent psoriasis treatment.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. More on methods
Paper Search
We performed a semantic search across over 138 million academic papers from the Elicit search engine. The search returned 200 total results for screening.
Screening
We screened in sources based on their abstracts that met these criteria:
- Target Population - Disease: Does the study include patients diagnosed with rheumatoid arthritis and/or psoriasis?
- Intervention Type: Does the study involve TNF inhibitor therapy?
- Clinical Outcomes: Does the study report clinical outcomes such as disease activity measures, symptom improvement?
- Study Design: Is the study design a randomized controlled trial, cohort study, etc.?
- Population Age: Does the study population include adult patients (≥18 years of age)?
- Study Type - Human Research: Is this a study conducted in human participants?
- Sample Size Adequacy: Does the study include 10 or more patients?
- Publication Type: Is this a full-text article?
Data Extraction
We asked a large language model to extract each data column from each paper, including key findings about the link between TNF inhibition and clinical outcomes, safety findings, and limitations.
Results
Characteristics of Included Studies
The review included 10 studies published between 2000 and 2025, comprising randomized controlled trials and systematic reviews.
| Study | Year | Type | Target Condition | TNF Inhibitor(s) | Sample Size | Primary Outcomes |
|---|---|---|---|---|---|---|
| L. Lemos et al. | 2014 | Systematic Review | Psoriatic Arthritis | Adalimumab, etanercept, golimumab, infliximab | Not mentioned | ACR20, ACR50, PASI75 |
| G. Cagnotto et al. | 2025 | Meta-Analysis | Psoriatic Arthritis | TNFi | 7857 | ACR50, HAQ, SF-36 MCS |
| E. Shmidt et al. | 2012 | Retrospective Cohort | Psoriasis as Adverse Event | Infliximab, adalimumab, etanercept | 56 | Complete or Partial Response |
| Mark Harrison et al. | 2008 | Prospective Observational | RA; Psoriasis as Adverse Event | Etanercept, infliximab, adalimumab | 9826 | Incidence of New-Onset Psoriasis |
| Angelique N. Collamer & D. Battafarano | 2010 | Literature Review | Psoriasis as Adverse Event | Infliximab, adalimumab, etanercept | 207 | Not mentioned |
| P. Mease et al. | 2000 | Randomized Controlled Trial | Psoriatic Arthritis | Etanercept | 60 | PsARC, ACR20, PASI |
| N. Bansback et al. | 2009 | Meta-Analysis | Psoriasis | Infliximab, adalimumab, etanercept | Not mentioned | PASI |
| U. Chaudhari et al. | 2001 | RCT | Psoriasis | Infliximab | 33 | Physician’s Global Assessment |
| K. Reich et al. | 2005 | RCT | Psoriasis | Infliximab | 378 | PASI |
| K. Thorlund et al. | 2012 | Meta-Analysis | Psoriatic Arthritis | Adalimumab, etanercept, golimumab, infliximab | Not mentioned | PsARC, HAQ, PASI |
Effects of TNF Inhibitors
Efficacy in Psoriatic Arthritis
TNF inhibitors produced large improvements in clinical response at 12 weeks compared to placebo. Physical function and health-related quality of life improved with significant results. TNFi also reduced radiographic progression.
Efficacy in Psoriasis
For moderate-to-severe plaque psoriasis, TNF inhibitors showed high efficacy, with infliximab achieving PASI 75 in the majority of patients.
Safety Profile
The safety profile of TNF inhibitors appeared favorable overall, though paradoxical new-onset psoriasis remains a recognized adverse event in patients treated for other indications. Incidence rates differ by agent and patient population.
Synthesis
The evidence reveals that TNF inhibitors effectively treat both psoriatic arthritis and moderate-to-severe psoriasis while presenting challenges related to paradoxical psoriasis development. Properties of TNF in relation to immune response play a vital role in these contrasting outcomes.
References
- E. Shmidt et al., 2012 - Link
- Mark Harrison et al., 2008 - Link
- Angelique N. Collamer et al., 2010 - Link
- P. Mease et al., 2000 - Link
- N. Bansback et al., 2009 - Link
- U. Chaudhari et al., 2001 - Link
- K. Reich et al., 2005 - Link
- K. Thorlund et al., 2012 - Link
- L. Lemos et al., 2014 - Link
- G. Cagnotto et al., 2025 - Link